Jörg Sievers

机构：ViiV Healthcare (United Kingdom) · ORCID：0000-0003-1723-8237

发表论文 35 篇 · 总被引 1322 次 · h-index 13

代表论文

• Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials (2018 · The Lancet · 被引 385)
• Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials (2019 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 214)
• Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial (2019 · The Lancet Infectious Diseases · 被引 198)
• Decreased plasma phospholipid concentrations and increased acid sphingomyelinase activity are accurate biomarkers for community-acquired pneumonia (2019 · Journal of Translational Medicine · 被引 71)
• Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis (2020 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 18)
• Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies (2020 · Journal of Infection and Public Health · 被引 16)